# SAFETY DATA SHEET



## 1. Identification

**Product identifier** Cyramza™

Other means of identification

**Item Code** VL7721, VL7678, VL7669

LY3009806 LY Number Recommended use Pharmaceutical **Recommended restrictions** None known.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

Eli Lilly and Company Company name Lilly Corporate Center **Address** Indianapolis, IN 46285

**United States** 

Telephone Phone: +1-317-276-2000

E-mail lilly msds@lilly.com

CHEMTREC: +1-800-424-9300 **Emergency phone number** 

2. Hazard(s) identification

Not classified. Physical hazards **Health hazards** Not classified. **OSHA** defined hazards Not classified.

Label elements

None. Hazard symbol Signal word None.

The mixture does not meet the criteria for classification. Hazard statement

**Precautionary statement** 

Prevention Not available. Not available. Response Not available. Storage Not available. Disposal Hazard(s) not otherwise

classified (HNOC)

None known.

Supplemental information None.

## 3. Composition/information on ingredients

#### **Mixtures**

Chemical name Common name and synonyms **CAS** number % Ramucirumab NA 1

Remaining components of this product are non-hazardous and/or are present at concentrations Composition comments

below reportable levels.

4. First-aid measures

Inhalation Call a physician if symptoms develop or persist.

Skin contact Rinse skin with water/shower. Get medical attention if irritation develops and persists.

Rinse with water. Get medical attention if irritation develops and persists. Eye contact

Get medical attention if symptoms occur. Ingestion

Most important Not available.

symptoms/effects, acute and

delayed

Material name: Cyramza™ SDS US

4820 Version #: 07 Revision date: 09-19-2019 Issue date: 11-20-2014

**General information** If you feel unwell, seek medical advice (show the label where possible).

5. Fire-fighting measures

Suitable extinguishing media

Unsuitable extinguishing

media

Use fire-extinguishing media appropriate for surrounding materials.

Not available.

Specific hazards arising from

the chemical

This product is an aqueous mixture which will not burn.

Special protective equipment and precautions for firefighters

Wear suitable protective equipment.

## 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Not available.

Methods and materials for containment and cleaning up

Prevent runoff from entering drains, sewers, or streams. Use absorbent/adsorbent material to solidify liquids. Clean up promptly by sweeping or vacuum. See Section 8 of the SDS for Personal

Protective Equipment.

**Environmental precautions** 

No specific precautions.

## 7. Handling and storage

Precautions for safe handling

Avoid contact with eyes, skin, and clothing. Wash hands thoroughly after handling. See Section 8 of the SDS for Personal Protective Equipment.

Conditions for safe storage, including any incompatibilities

Keep refrigerated Store at: 2 - 8 °C. Do not allow material to freeze. Do not shake material. Protect

from light.

## 8. Exposure controls/personal protection

### Occupational exposure limits

Lilly (LEG) Components	Туре	Value	
Ramucirumab	TWA (12hrs)	110 ug/m3	
	TWA (8hrs)	165 ug/m3	

Biological limit values

No biological exposure limits noted for the ingredient(s).

Exposure guidelines

Occupational Exposure Limit (OEL): Not established

Appropriate engineering

controls

Contained handling practices preferred. If open handling is necessary, use control measures (i.e. ventilated enclosure, local exhaust ventilation) to maintain airborne levels below the occupational

exposure level (OEL).

## Individual protection measures, such as personal protective equipment

**Eye/face protection** Safety glasses with side shields recommended. If splash potential or dusty operations, wear

goggles/faceshield.

Skin protection

Hand protection Chemical resistant gloves.

Other While monoclonal antibodies are not anticipated to be readily absorbed through the skin, wear

impervious gloves and body covering (i.e. lab coat) to minimize skin contact.

**Respiratory protection** Not required under normal conditions for liquid handling activities. If handling powder forms,

consider appropriate respiratory protection to maintain exposure levels below occupational

exposure level (OEL).

Thermal hazards Not available.

General hygiene considerations

Engineering controls should be used as the primary means to control workplace exposures. Follow good workplace hygiene practices such as washing hands after handling this material.

This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered occupationally relevant and potential bioavailability through inhalation is minimal.

### 9. Physical and chemical properties

**Appearance** Clear to opalescent.

Physical state Liquid.

Form Aqueous solution.

Material name: Cyramza™

Color Colorless to light yellow.

Odor Not available.
Odor threshold Not available.
pH Not available.
Melting point/freezing point Not available.
Initial boiling point and boiling Not available.

range

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not applicable.

Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

(%)

Not available.

Not available.

Explosive limit - lower (%) Not available.

Explosive limit - upper (%) Not available.

Vapor pressure Not available.

Vapor density Not available.

Relative density Solubility(ies)

Solubility (water) Not available.

Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperature Not available.

Decomposition temperature Not available.

Viscosity Not available.

Other information

**Explosive properties** Not explosive.

Oxidizing properties No oxidizing properties.

pH in aqueous solution Neutral

## 10. Stability and reactivity

**Reactivity** Not water reactive.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous Hazardous polymerization does not occur.

reactions

Conditions to avoid None under normal conditions.

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

No hazardous decomposition products are known.

### 11. Toxicological information

## Information on toxicological effects

Acute toxicity Not applicable.

Skin corrosion/irritation

Due to lack of data the classification is not possible.

Serious eye damage/eye

Due to lack of data the classification is not possible.

irritation

Respiratory or skin sensitization

**Respiratory sensitization**Due to lack of data the classification is not possible. **Skin sensitization**Due to lack of data the classification is not possible.

Material name: Cyramza™ sps us

3/5

4820 Version #: 07 Revision date: 09-19-2019 Issue date: 11-20-2014

Germ cell mutagenicity This substance is a monoclonal antibody. It does not possess mutagenic potential. Mutagenicity

testing has not been conducted.

Based on available data, the classification criteria are not met.

No test data available. Not listed by IARC, NTP, ACGIH or OSHA.

Due to lack of data the classification is not possible.

#### IARC Monographs. Overall Evaluation of Carcinogenicity

Carcinogenicity

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

No test data available. Reproductive toxicity

> VEGF is a critical mediator of angiogenesis that occurs across several stages of the female reproductive cycle, pregnancy, and embryo-fetal development. Interference of VEGF signaling through the use of transgenic models (for example, knockout mice), nonproprietary antibodies against VEGF or its receptors against VEGFR-2 have been shown to block angiogenesis and functioning or development of tissues critical for mammalian reproduction and development.

Based on available data, the classification criteria are not met.

Specific target organ toxicity -

single exposure

Due to lack of data the classification is not possible.

Specific target organ toxicity -

repeated exposure

Animal studies have reported the following effects: Kidney effects. (glomerulonephritis) Ovarian

changes. (follicular mineralization) (drug substance) (intravenous) Based on available data, the classification criteria are not met.

**Aspiration hazard** Not applicable.

Effects reported with therapeutic administration: Increased risk of hemorrhage, serious arterial **Further information** 

thromboembolic events (ATEs) including myocardial infaction, cardiac arrest, cerebrovascular

accident, cerebral ischemia, increased incidence of severe hypertension.

This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered

occupationally relevant and potential bioavailability through inhalation is minimal.

## 12. Ecological information

Not expected to be harmful to aquatic organisms. **Ecotoxicity** 

Persistence and degradability Not available. Bioaccumulative potential Not available. Not available. Mobility in soil Other adverse effects Not available.

#### 13. Disposal considerations

**Disposal instructions** Dispose in accordance with all applicable regulations.

### 14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

**IMDG** 

Not regulated as dangerous goods.

Transport in bulk according to Not available.

Annex II of MARPOL 73/78 and

the IBC Code

### 15. Regulatory information

This product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard **US federal regulations** 

Communication Standard, 29 CFR 1910.1200.

**Toxic Substances Control Act (TSCA)** 

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

Material name: Cyramza™ SDS US

### **CERCLA Hazardous Substance List (40 CFR 302.4)**

Not listed.

### SARA 304 Emergency release notification

Not regulated.

## OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Not listed.

### Superfund Amendments and Reauthorization Act of 1986 (SARA)

### SARA 313 (TRI reporting)

Not regulated.

#### Other federal regulations

#### Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

## Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

Not regulated.

(SDWA)

#### International Inventories

Country(s) or regionInventory nameOn inventory (yes/no)\*CanadaDomestic Substances List (DSL)NoCanadaNon-Domestic Substances List (NDSL)NoUnited States & Puerto RicoToxic Substances Control Act (TSCA) InventoryNo

## 16. Other information, including date of preparation or last revision

 Issue date
 11-20-2014

 Revision date
 09-19-2019

Version # 07

**List of abbreviations** LEG: Lilly Exposure Guideline.

TWA: Time Weighted Average

**Disclaimer** As of the date of issuance, we are providing available information relevant to the handling of this

material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature

5/5

which may accompany the finished product.

For additional information contact:

Eli Lilly and Company Hazard Communication +1-317-651-9533

Revision information Handling and storage: Conditions for safe storage, including any incompatibilities

Material name: Cyramza™ sps us

4820 Version #: 07 Revision date: 09-19-2019 Issue date: 11-20-2014

<sup>\*</sup>A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).